Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

Suven Life Sciences today announced that the first patient has been randomized in its Phase-2b clinical trial evaluating ...

Hyderabad: Suven Life Sciences has announced that the first patient has been randomized in its Phase-2b clinical trial ...

A low-emulsifier-containing diet led to a threefold increased likelihood of improvement in symptoms of Crohn’s disease ...

Findings reveal that a structured home rehabilitation program boosts lung function and quality of life in bronchiectasis ...

Vegan diets may enhance performance in semi-professional soccer players, but attention to protein and nutrient intake is crucial for muscle preservation.

Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong ...

Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 ...